Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18780464 | 0.82 | KCNH2 (0.37) | HTR2AHTR2CPDE2A | |
| SCHEMBL19629265 | 0.82 | TSHR (0.42) | TSHRRORCPDE2A | |
| SCHEMBL12599943 | 0.79 | GABRA1 (0.37) | TSHRHTR2AHTR2C | |
| SCHEMBL14457121 | 0.78 | TSHR (0.39) | TSHRRORCPDE2A | |
| SCHEMBL18552712 | 0.78 | AR (0.40) | TSHR | |
| SCHEMBL27548299 | 0.77 | TSHR (0.38) | TSHRRORCPDE2A | |
| SCHEMBL19121860 | 0.77 | LMNA (0.41) | TSHRRORCPDE2A | |
| SCHEMBL22871213 | 0.77 | TSHR (0.47) | TSHRRORC | |
| SCHEMBL12735695 | 0.77 | LMNA (0.41) | TSHRRORCPDE2A | |
| SCHEMBL16117013 | 0.77 | LMNA (0.41) | TSHRRORCPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-3397639-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| US-10646486-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180110776-A1 | POLYCYCLICCARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110776-A1 | POLYCYCLICCARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | PAICS, RPL5, CYP3A43 | TSHR 4039/4885HTR2A 3768/4885HTR2C 3942/4885 |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | TSHR 4706/4885HTR2A 4349/4885HTR2C 4095/4885 |
| US-10646486-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | CPS1, PAICS, C9 | TSHR 3413/4885HTR2A 4095/4885HTR2C 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.